The Respiratory Inhaler Devices market is expected to grow from USD 36.27 billion in 2019 to USD 45.89 billion by 2025 at a CAGR of 4% from 2019 to 2025.
Respiratory inhalator devices are medical devices are wont to assist a patient encountering respiration issues ensuing from metastasis disorders like pathology, asthma, COPD and respiratory disorder et al. On the premise of product kind, the market has been divided into dry powder inhalator (DPI), metered-dose inhalator (MDI) and the nebuliser. Nebuliser is more sub-segmented into a compressed gas nebulizer, ultrasonic nebulizer and mesh nebulizer. The global market is segregated on the basis of Disease Indication as Asthma, COPD, Pulmonary Arterial Hypertension, and Other Respiratory Disease. Based on Technology the market is segmented in Manually Operated Inhaler Devices and Digitally Operated Inhaler Devices. Based on Product the market is segmented in Dry Powder Inhaler, Metered Dose Inhaler, and Nebulizer.
The global market report provides geographical analysis covering regions, such as North America, Europe, Asia-Pacific, and the Rest of the World. The market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd, and others are among the major players in the market. The companies studied in terms of product strategy and various n several growths and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.
The global Respiratory Inhaler Devices market has been segmented as below:
By Disease Indication
By Technology
By Product
By Region
Respiratory Inhaler Devices Market, By Company
The report covers the below scope:
The years considered for the study are as follows:
Report Scope:
The global market report scope includes a detailed study covering underlying factors influencing the industry trends. The report covers the analysis of regional and country-level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes a detailed competitive outlook covering market shares and profiles key participants in the market share. Major industry players with significant revenue share include AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd, and others.
Why to Buy this Report:
Target Audience:
The report targeted the existing players in the industry is as follows:
Free and Paid Customization based on the requirement
Report Content
1. Introduction
1.1 Key Insights
1.2 Report Overview 1.3 Markets Covered 1.4 Stakeholders 2. Research Methodology 2.1 Research Scope 2.2 Market Research Process 2.3 Research Data Analysis 2.4.1 Secondary Research 2.4.2 Primary Research 2.4.3 Models for Estimation 2.5 Market Size Estimation 2.5.1 Bottom-Up Approach - Segmental Market Analysis 2.5.2 Top-Down Approach - Parent Market Analysis 3. Executive Summary 4. Market Overview 4.1 Introduction 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.2.4 Challenges 4.2 Porter's Five Force Analysis 5. Respiratory Inhaler Devices Market, By Disease Indication 5.1 Introduction 5.2 Asthma 5.2.1 Market Overview 5.2.2 Market Size and Forecast 5.3 COPD 5.3.1 Market Overview 5.3.2 Market Size and Forecast 5.4 Pulmonary Arterial Hypertension 5.4.1 Market Overview 5.4.2 Market Size and Forecast 5.5 Others Respiratory Disease 5.5.1 Market Overview 5.5.2 Market Size and Forecast 6. Respiratory Inhaler Devices Market, By Technology 6.1 Introduction 6.2 Manually Operated Inhaler Devices 6.2.1 Market Overview 6.2.2 Market Size and Forecast 6.3 Digitally Operated Inhaler Devices 6.3.1 Market Overview 6.3.2 Market Size and Forecast 7. Respiratory Inhaler Devices Market, By Product 7.1 Introduction 7.2 Dry Powder Inhaler 7.2.1 Market Overview 7.2.2 Market Size and Forecast 7.3 Metered Dose Inhaler 7.3.1 Market Overview 7.3.2 Market Size and Forecast 7.4 Nebulizer 7.4.1 Market Overview 7.4.2 Market Size and Forecast 8. Respiratory Inhaler Devices Market, By Geography 8.1 Introduction 8.2 North America 8.2.1 North America Respiratory Inhaler Devices, By Disease Indication 8.2.2 North America Respiratory Inhaler Devices, By Technology 8.2.3 North America Respiratory Inhaler Devices, By Product 8.3 Europe 8.3.1 Europe Respiratory Inhaler Devices, By Disease Indication 8.3.2 Europe Respiratory Inhaler Devices, By Technology 8.3.3 Europe Respiratory Inhaler Devices, By Product 8.4 Asia-Pacific 8.4.1 Asia-Pacific Respiratory Inhaler Devices, By Disease Indication 8.4.2 Asia-Pacific Respiratory Inhaler Devices, By Technology 8.4.3 Asia-Pacific Respiratory Inhaler Devices, By Product 8.5 Rest of the World 8.5.1 Rest of the World Respiratory Inhaler Devices, By Disease Indication 8.5.2 Rest of the World Respiratory Inhaler Devices, By Technology 8.5.3 Rest of the World Respiratory Inhaler Devices, By Product 9. Competitive Insights 9.1 Key Insights 9.2 Company Market Share Analysis 9.3 Strategic Outlook 9.3.1 Mergers & Acquisitions 9.3.2 New Product Development 9.3.3 Portfolio/Production Capacity Expansions 9.3.4 Joint Ventures, Collaborations, Partnerships & Agreements 9.3.5 Others 10. Company Profiles 10.1 AstraZeneca 10.1.1 Company Overview 10.1.2 Product/Service Landscape 10.1.3 Financial Overview 10.1.4 Recent Developments 10.2 Beximco Pharmaceuticals Ltd. 10.2.1 Company Overview 10.2.2 Product/Service Landscape 10.2.3 Financial Overview 10.2.4 Recent Developments 10.3 Boehringer Ingelheim GmbH 10.3.1 Company Overview 10.3.2 Product/Service Landscape 10.3.3 Financial Overview 10.3.4 Recent Developments 10.4 Cipla Ltd. 10.4.1 Company Overview 10.4.2 Product/Service Landscape 10.4.3 Financial Overview 10.4.4 Recent Developments 10.5 GlaxoSmithKline plc 10.5.1 Company Overview 10.5.2 Product/Service Landscape 10.5.3 Financial Overview 10.5.4 Recent Developments 10.6 Koninklijke Philips N.V. 10.6.1 Company Overview 10.6.2 Product/Service Landscape 10.6.3 Financial Overview 10.6.4 Recent Developments 10.7 Merck & Co., Inc. 10.7.1 Company Overview 10.7.2 Product/Service Landscape 10.7.3 Financial Overview 10.7.4 Recent Developments 10.8 OMRON Healthcare Europe B.V. 10.8.1 Company Overview 10.8.2 Product/Service Landscape 10.8.3 Financial Overview 10.8.4 Recent Developments 10.9 PARI Medical Holding 10.9.1 Company Overview 10.9.2 Product/Service Landscape 10.9.3 Financial Overview 10.9.4 Recent Developments 10.10 Teva Pharmaceutical Industries Ltd 10.10.1 Company Overview 10.10.2 Product/Service Landscape 10.10.3 Financial Overview 10.10.4 Recent Developments
The global Respiratory Inhaler Devices market has been segmented as below:
By Disease Indication
By Technology
By Product
By Region
Top 10 Companies in Respiratory Inhaler Devices Market,